开发一种红细胞-MHC-I结合物用于癌症治疗
Yuehua Liu1,2,3,4, Xiaoqian Nie2,3,4, Xingyun Yao1,2,3,4
1Zhejiang University, School of Basic Medical Science, Hangzhou, Zhejiang, China.
Cell discovery
|September 30, 2024
概括
这项研究开发了一种新的癌症免疫疗法,使用修饰的红细胞 (MHC-I‒Ery) 激活T细胞并抑制瘤生长. 这种方法在治疗人类乳头瘤病毒相关癌症方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 成熟的红细胞通常缺乏主要基因相容性复合 (MHC) 蛋白质.
- 之前关于红细胞上MHC分子的报道缺乏定义的功能.
- 这项研究探讨了红细胞在免疫治疗中的新应用.
研究的目的:
- 调查使用MHC I类 (MHC-I) 和抗原来设计的红细胞在癌症免疫治疗中的潜力.
- 评估MHC-I‒Ery在激活T细胞和抑制瘤生长方面的疗效.
- 评估MHC-I‒Ery在临床应用中的安全性和耐受性.
主要方法:
- 红细胞与融合蛋白 (MHC-I‒Ery) 结合,将抗原 (HPV16 E6/E7) 与MHC I 类连接起来.
- 使用来自宫癌患者的外周血液单核细胞 (PBMC) 评估了抗原特异性CD8+T细胞激活.
- 在体内研究中,对具有抗原阳性瘤的小鼠进行MHC-I‒Ery单疗法.
- 在治疗后分析了脏中的免疫细胞群.
- 在非人类灵长类动物中评估了安全性和耐受性.
主要成果:
- MHC-I‒Ery有效地激活了来自HPV16+宫癌患者的PBMC中的抗原特异性CD8+T细胞.
- 在小鼠中,MHC-I-Ery单一疗法抑制了抗原阳性瘤生长.
- 治疗导致CD8+ T细胞快速激活,减少了大中的抑制性髓状细胞,诱导了全身抗瘤活性.
- 非人类灵长类动物的安全性和耐受性支持临床潜力.
结论:
- 仅用抗原-MHC-I复合体设计的红细胞可以有效地刺激免疫系统.
- 这代表了推进癌症免疫治疗的新且有前途的战略.
- MHC-I‒Ery证明了治疗人类乳头瘤病毒相关癌症的巨大潜力.
相关概念视频
Antigens Involved in Adaptive Immunity
468
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
468
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


